Xynomic Pharmaceuticals Holdings Inc represents a strong commitment to innovation and excellence in the pharmaceutical industry. The company's corporate philosophy focuses on developing and commercializing breakthrough oncology treatments to improve patients' lives. With a vision to become a global leader in precision medicine, Xynomic Pharmaceuticals prioritizes research and collaboration to unlock the full potential of targeted therapies. The company's core values include integrity, patient-centricity, and scientific rigor. By combining cutting-edge science with a dedication to clinical advancement, Xynomic Pharmaceuticals strives to make a meaningful impact in the field of oncology and bring hope to patients worldwide.

Xynomic Pharmaceuticals Holdings Inc is primarily present in the United States and China.

Xynomic Pharmaceuticals Holdings Inc has achieved significant milestones in its operations. The company successfully completed the Phase 1/2 clinical trials for its lead product candidate, abexinostat, a histone deacetylase inhibitor (HDACi). It has also obtained Fast Track designation from the U.S. FDA for abexinostat in combination with rituximab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Xynomic has received Orphan Drug Designation from the FDA for its other clinical-stage product, XP-102 (bucillamine), for the treatment of patients with non-alcoholic steatohepatitis. The company's achievements highlight its dedication to advancing innovative therapies for better patient outcomes.

Xynomic Pharmaceuticals Holdings Inc has a rich history and background in the pharmaceutical industry. Established in [insert year], the company has dedicated itself to the development of innovative therapies for various diseases. Xynomic Pharmaceuticals focuses on targeting unmet medical needs, prioritizing patient well-being and improved outcomes. With a strong emphasis on research and development, the company has actively pursued collaborations and partnerships to advance its pipeline of potential drugs. As a leader in the industry, Xynomic Pharmaceuticals continues to strive towards delivering breakthrough treatments that positively impact patients' lives.

The main competitors of Xynomic Pharmaceuticals Holdings Inc in the market include established pharmaceutical companies such as Pfizer, Novartis, Roche, and Johnson & Johnson. These multinational companies have a strong presence in the pharmaceutical industry and offer a wide range of therapeutic products and services. Xynomic Pharmaceuticals Holdings Inc competes with these companies by focusing on its innovative drug development pipeline and unique market positioning.

Xynomic Pharmaceuticals Holdings Inc is primarily active in the biopharmaceutical industry.

The business model of Xynomic Pharmaceuticals Holdings Inc is focused on developing innovative cancer treatments. The company aims to identify and license promising drug candidates, and then advance them through clinical trials and regulatory approval processes. Xynomic Pharmaceuticals uses a strategic approach that combines in-house development with collaborations and partnerships to maximize resources and expertise. By targeting unmet medical needs and leveraging its expertise in oncology, Xynomic Pharmaceuticals aims to bring new and effective treatments to patients worldwide.

KGV-d ei saa praegu Xynomic Pharmaceuticals Holdings jaoks arvutada.

KUV-d ei ole võimalik hetkel Xynomic Pharmaceuticals Holdings jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele Xynomic Pharmaceuticals Holdings on 4/10.

Praegu ei saa Xynomic Pharmaceuticals Holdings käivet arvutada.

Praegu ei ole võimalik kasumit Xynomic Pharmaceuticals Holdings jaoks arvutada.

Xynomic Pharmaceuticals Holdings Inc is a rising biotech company focused on developing novel therapies for treating various types of cancer. Its business model includes research and development, clinical trials, manufacturing, and distribution of drugs. The company's research and development department is the core of the organization, where experts work on identifying and developing new compounds to combat cancer cells. Clinical trials are conducted to investigate the efficacy and safety of promising drug candidates in humans. Manufacturing involves producing the drug once clinical trials are successfully completed, often in collaboration with external partners. Xynomic Pharmaceuticals currently does not have any drugs on the market but plans to seek FDA approval in the near future. The company has several promising drug candidates, including Abexinostat, XP-105, and XP-102, which have shown positive results in clinical trials. Overall, Xynomic Pharmaceuticals is an emerging biotech company dedicated to developing innovative cancer medications.

Xynomic Pharmaceuticals Holdings maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Xynomic Pharmaceuticals Holdings jaoks arvutada või ettevõte ei maksa dividende välja.

Xynomic Pharmaceuticals Holdings ISIN on US98421X1028.

Xynomic Pharmaceuticals Holdings tähis on XYNO.

Viimase 12 kuu jooksul maksis Xynomic Pharmaceuticals Holdings dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Xynomic Pharmaceuticals Holdings tõenäoliselt dividendi summas 0 USD.

Xynomic Pharmaceuticals Holdings praegune dividenditootlus on .

Xynomic Pharmaceuticals Holdings maksab kvartaalset dividendi. See makstakse välja kuudel .

Xynomic Pharmaceuticals Holdings maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Xynomic Pharmaceuticals Holdings on liigitatud sektorisse 'Tervis'.

Viimase Xynomic Pharmaceuticals Holdings dividendide saamiseks 3.10.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 3.10.2024.

Viimane dividendimakse toimus 3.10.2024.

Aastal 2023 maksis Xynomic Pharmaceuticals Holdings 0 USD dividende.

Xynomic Pharmaceuticals Holdings dividendid makstakse välja USD.